Zentalis Pharmaceuticals (ZNTL) Cash from Financing Activities (2019 - 2026)

Zentalis Pharmaceuticals' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at -$1.1 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 694.18% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$5.6 million (down 2028.97% YoY), while the FY2025 annual figure was -$4.3 million, down 4064.81% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$1.1 million, up from -$4.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $236.6 million in Q2 2023, with the low at -$4.6 million in Q4 2025.
• The 5-year median for Cash from Financing Activities is $249000.0 (2023), against an average of $35.2 million.
• The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities surged 66383.23% in 2022, then sank 694.18% in 2026.
• Zentalis Pharmaceuticals' Cash from Financing Activities stood at $49.7 million in 2022, then plunged by 99.38% to $309000.0 in 2023, then tumbled by 70.23% to $92000.0 in 2024, then sank by 5084.78% to -$4.6 million in 2025, then soared by 75.51% to -$1.1 million in 2026.
• Business Quant data shows ZNTL's Cash from Financing Activities at -$1.1 million in Q1 2026, -$4.6 million in Q4 2025, and $115000.0 in Q3 2025.